Novartis lung drug rivals Pfizer's

Share this article:
Novartis events draw DOJ lawsuits
Novartis lung drug rivals Pfizer's

Novartis's breakthrough-therapy lung drug codenamed LDK378 had a 58% response rate among Phase-I clinical trial patients, according to a study published in the New England Journal of Medicine Thursday.

The experimental treatment for non-small cell lung cancer is one of the company's three drugs to score the breakthrough label last year, a tag which accelerates the FDA review process.

The study found that the treatment, which targets the anaplastic lymphoma kinase gene and is known by the name ceritinib, worked both in patients who had and had not been treated with Xalkori, Pfizer's ALK-targeting medication. The ability to have an impact in both populations is of note because patients typically develop resistance to Xalkori.

Bernstein analyst Tim Anderson noted in a January report that Novartis's experimental treatment can cross the blood-brain barrier, meaning it has “activity in brain metastases,” unlike Pfizer's Xalkori.

Although Xalkori gets name-checked in the NEJM study, this turf war is not limited to Novartis and Pfizer. Ariad and Chugai also have pipeline treatments that target the anaplastic lymphoma kinase gene, and anticipate regulatory filings in the near future—as in 2014 to 2016.

The ability to file the treatment this year would keep the expected 2014 pipeline full: the company expects 10 filings this year, including certinib.

Of the three breakthrough designations Novartis earned last year, ceritinib's readout is a positive. An FDA panel published its negative opinion of breakthrough heart drug serelaxin before Thursday's review, and the company is not expecting to file its muscle degenerating medication bimagrumab until 2016.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...